News & Updates

TVALA Drug Trial

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study...

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the...

MOLECULAR MECHANISMS OF REDOX REGULATION IN INFLAMMATION

We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first...

TVALA Fortune Journal

Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation

Therapeutic potential of drug interventions on microglia in ALS

Dr. Susanne Petri, Hannover Medical School, Department of Neurology, in Hannover, Germany presented progress on her project...

Researchers develop ultra-high-performance method to analyze oxylipins

NDR contributed to the work that was published by Dr. Adriano Chaves-Filho and the Dr. Sayuri Miyamoto team. To profile oxylipins in...

NDR starts clinical trial with TVALA

Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS....

Innovate Indiana recognizes Dr. Chandler Walker for secretome work

Indiana University researcher Chandler Walker, Ph.D., developed a stem cell-based secretome therapy that influences both the central and...

NDR publishes novel study

The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R...